| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Business combination transaction with Calidi Biotherapeutics anticipated to be completed on September 12, 2023
Gross proceeds made available to Calidi Biotherapeutics from transaction will total approximately $28 million, including funds held in First Light Acquisition Group's trust account before deducting transaction expenses and debt repayments
In addition, Calidi secured a forward purchase agreement for up to $10 million with a consortium including Meteora Capital LLC, Great Point Capital LLC, and Funicular Funds, LP
Listed company to be named Calidi Biotherapeutics, Inc.
Common stock and warrants approved for listing on the New York Stock Exchange American under the ticker symbols "CLDI" and "CLDI WS," respectively; expected to begin trading on September 13, 2023
Posted In: FLAG
